Part 2 of interview with Dr. Peter Hollands
Modern stem-cell advancements in umbilical cord blood have rendered human embryonic stem-cell research unnecessary according to a prestigious UK researcher, who calls cord blood the “realistic future of stem-cell technology.”
In this second part of an exclusive interview with LifeSiteNews.com, Dr. Peter Hollands, the Chief Science Officer of the UK Blood Bank and early pioneer of embryonic stem-cell research, explains that embryonic stem-cell researchers will keep their public mandate unless a vast media campaign educates the public about the superior benefits and proven cures of cord blood.
In a previous interview, Dr. Hollands explained that the success of cord blood depends on its superior “mesenchymal stem-cells” found in the blood of the placenta and umbilical cord after a baby’s birth. These stem-cells possess unique properties giving them “just as much potential as embryonic stem cells but without all of the related objections and technical concerns.” (http://www.lifesite.net/ldn/2006/aug/06081804.html)
“As a scientist, and even as a lay person, it is simple to see that cord blood as a source of stem cells for therapy and research is the easiest route to take,” says Dr. Hollands. “We have a never ending supply of cord blood and if we can start to collect and store this valuable resource instead of discarding it then we will start to make real progress in stem cell therapy and research.”
However, Dr. Hollands takes issue with those who contend that patient therapies can be obtained from human embryonic stem-cells.
“To claim that there are enough ‘spare’ embryos in IVF clinics is nonsense,” says Dr. Hollands. “These embryos could not support the demand for stem cell transplants” adding embryonic stem cells also have a tendency “to form tumors on transplantation”. [snip] Lifesitenews.com